Brett Wingeier, PhD

Brett Wingeier, PhD, is a biomedical engineer, neuroscientist, and R&D leader with 25+ years of experience in bringing complex, data-driven neurotech to market across multiple indications and platforms. Dr. Wingeier is currently Vice-President of Research and Development at NeuroPace, a publicly-traded neuromodulation company focusing on responsive brain stimulation for treatment of epilepsy. Previously, he served as CEO and co-founder of Magnus Medical, bringing to market the SAINT technology for data-driven, individually-targeted treatment of major depression, and CTO of Halo Neuroscience, where he created Halo Sport, a non-invasive wearable neuromodulation platform for human performance applications. Holding a BSE and Ph.D. in Biomedical Engineering from Tulane University, Dr. Wingeier has published research in biosignals and neural interfaces and is a US registered patent agent with more than 80 issued patents.